To include your compound in the COVID-19 Resource Center, submit it here.
Top-line data from 8 patients with XLRS in an open-label, U.S. Phase I/II trial showed that low- and mid-dose
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury